Executive Pay Matters

Second-quarter pay-for-performance update for the biopharma industry: uncertain expectations

| Mitchell Bardolf and Jang Han

For the biopharma industry, 2017 is proving to be a year of uncertainty. Margins are being squeezed, and companies will have to consider ways to improve business and operating models to gain efficiencies that offset rising cost pressures in order to meet investor expectations and maximize returns. The outcome could have implications for setting performance targets for 2018 incentives.

Mitchell Bardolf and Jang Han

(A link to this page will be included in your message)


* All fields marked with a red asterisk are required:

Separate multiple email addresses with commas.